A Randomized Phase 3 Open Label Study of Nivolumab versus Bevacizumab and Multiple Phase 1 Safety Cohorts of Nivolumab or Nivolumab in Combination with Ipilimumab Across Different Lines of Glioblastoma

Diseases and Conditions Researched

Brain and Nervous System

What is the purpose of this trial?

The purpose of the study is to understand the safety, tolerability and efficacy of Nivolumab as a single agent or in combination with Ipilimumab versus Bevacizumab in patients diagnosed with Recurrent Glioblastoma (GBM).

Participation Guidelines

Age: Any

Click here for detailed participation information for this trial.

Sponsor: Bristol-Myers Squibb Company
Last Updated:
Study HIC#: 1312013141